In 2023, ReNAgade Therapeutics launched with $300 million to exploit an “all in one” technology solution for RNA-based therapies. That same year, Tome Biosciences emerged from stealth with $213 ...

Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week.

Marty Makary’s exit as head of the Food and Drug Administration is giving the biotech industry hope for stability after ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Dr. Andrew Snyder (Monash University) joins the show to discuss the current biotech landscape: rising M&A and IPO activity, ...

Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting ...

This biotech firm develops therapies for rare pulmonary diseases, leveraging proprietary drug delivery technology in the U.S.

Intel, Qualcomm, and Micron fall as investors opt to lock in profits following a breakneck rally in chip stocks. Trump’s China summit threatens the AI boom, Ford gets into the energy storage business, ...

CBSET plans to build a 110K SF life sciences facility in Waltham, the Boston Business Journal first reported. The new ...

The biotech group has struggled as a whole in 2025, but analysts say the innovation that has always supported the biotech ...

Case study presented highlighted clinical experience with revyve® in complex wound care. WINNIPEG, Manitoba, May 13, 2026 ...